FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BERGER FRANKLIN M					2. Issuer Name and Ticker or Trading Symbol Kezar Life Sciences, Inc. [ KZR ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
	ZAR LIFE S	SCIENCES, INC			3. Date of Earliest Transaction (Month/Day/Year) 06/24/2020						Officer below)	(give title		Other (s below)	specify	
4000 SHORELINE COURT, SUITE 300  (Street) SOUTH SAN FRANCISCO CA 94080  (City) (State) (Zip)			94080	4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							S. Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  1. Title of Security (Instr. 3)  2. Transaction 2A. Deemed 3. 4. Securities Acquired (A) or 5. Amount of 6. Ownership 7. Nature																
Date (Month/Da				h/Day/Ye	ear)   i	Execution Date, if any (Month/Day/Year		Transaction Code (Instr. 8)  Transaction Disposed C 5)		d Of (D) (Instr. 3, 4 and		Benefici	ally Following d	(D) or	or Indirect nstr. 4)	of Indirect Beneficial Ownership (Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	se (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr 8)		n of		6. Date Exercisable ar Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Ownership Form:	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$5.6	06/24/2020		A		8,896		(1)	06/23/2030	Common Stock	8,896	\$0.00	8,896		D	

## **Explanation of Responses:**

1. One-hundred percent (100%) of the shares subject to the option shall vest on 6/24/2021, subject to Reporting Person continuing to provide service through such date.

## Remarks:

/s/ Marc Belsky, Attorney-in-**Fact** 

06/26/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.